arrow
L

Louis M. Staudt

national institutes of health
H指数:145
被引数:9.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Axes of biological variation in diffuse large B cell lymphoma

弥漫大B细胞淋巴瘤的生物变异轴

2026-01-150
PRE
An Assessment of Kinase Selectivity; Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) Inhibitors

对激酶选择性的评估;几种布鲁顿酪氨酸激酶(BTK)抑制剂的酶抑制动力学及体外活性

2025-11-180
OAAI
Cooperative role of distinctive TP53 and PTEN combined loss in the peripheral T cell lymphoma–GATA3 molecular subgroup

TP53和PTEN独特性共同缺失在周围T细胞淋巴瘤-GATA3分子亚组中的协同作用

2025-10-170
PRE
Development and Validation of a Gene Expression Signature to Predict Early Events in Patients with Follicular Lymphoma

开发和验证一种用于预测滤泡性淋巴瘤患者早期事件的基因表达谱

2025-09-220
OAAI
High-grade B-cell lymphoma, not otherwise specified: an LLMPP study.

高级别B细胞淋巴瘤,非其他特指类型:一项LLMPP研究。

2025-07-210
OAAI
The Phenotypic Landscape of Anaplastic Large Cell Lymphoma Supports a New Molecular Classification: An LLMPP Study

间变性大细胞淋巴瘤的表型景观支持新的分子分类: 一项LLMPP研究

2025-03-010
PRE
Refining Diagnostic Subtypes of Peripheral T-Cell Lymphoma Using a Multiparameter Approach

使用多参数方法细化外周T细胞淋巴瘤的诊断亚型

2025-02-010
PRE
Multi- Component, Time- Course screening to develop combination cancer therapies based on synergistic toxicity

多组分,时程筛选,以开发基于协同毒性的联合癌症疗法

2024-11-250
PRE
A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma

一项关于达鲁珠单抗、卡非佐米和地塞米松(DKd)在高危冒烟型多发性骨髓瘤患者中的2期适应性研究

BLOOD
IF23.1
2024-11-050
PRE
Phase lb/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naive Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease

维奈克拉、依鲁替尼、泼尼松、奥滨尤妥珠单抗和来那度胺(ViPOR)在复发/难治性及初治套细胞淋巴瘤中的lb/2期研究:安全性、有效性和微小残留病初步分析

BLOOD
IF23.1
2024-11-050
PRE
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
2024-06-205
OAAI
BTK drives neutrophil activation for sterilizing antifungal immunity
2024-05-025
OAAI
Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
2024-04-251
OA
Molecular mechanism of action and targets of glucocorticoids in lymphoma therapy
2024-03-220
PRE
NCI Cancer Research Data Commons: Resources to Share Key Cancer Data
2024-03-157
OAAI